Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Pharmacokinetics of Ferric bepectate - a new intravenous iron drug for treating iron deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Oral Immunosuppressive Treatment of Myasthenia Gravis in Denmark: A Nationwide Drug Utilization Study, 1996-2013

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Novel Treatment Options

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), play an important role in glucose homeostasis by potentiating glucose-induced insulin secretion. Furthermore, GLP-1 has been reported to play a role in glucose homeostasis by inhibiting glucagon secretion and delaying gastric emptying. As the insulinotropic effect of GLP-1 is preserved in patients with type 2 diabetes (T2D), therapies based on GLP-1 have been developed in recent years, and these have proven to be efficient in the treatment of T2D. The endogenous secretion of both GIP and GLP-1 is stimulated by glucose in the small intestine, and the release is dependent on the amount. In this work, we developed a semi-mechanistic model describing the release of GIP and GLP-1 following ingestion of various glucose doses in healthy volunteers and patients with T2D. In the model, the release of both hormones is stimulated by glucose in the proximal small intestine, and no differences in the secretion dynamics between healthy individuals and patients with T2D were identified after taking differences in glucose profiles into account. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalBasic & clinical pharmacology & toxicology
Volume121
Issue number4
Pages (from-to)290-297
Number of pages7
ISSN1742-7843
DOIs
Publication statusPublished - Oct 2017

    Research areas

  • Journal Article

ID: 51414110